Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5698-5708

  Nagant, C ^a   Pitts, B ^b   Nazmi, K ^c   Vandenbranden, M ^a   Bolscher, J G ^c   Stewart, P S ^b   Dehaye, J P ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b MONTANA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; ETHIDIUM BROMIDE; IG 13; IG 19; IG 25; KD 13; LACTATE DEHYDROGENASE; LL 13; LL 13 25; LL 13 31; LL 13 37; LL 19; LL 19 37; LL 25; LL 25 37; LL 31; LL 7 25; LL 7 31; LL 7 37; PEPTIDE FRAGMENT; POLYPEPTIDE ANTIBIOTIC AGENT; PROPIDIUM IODIDE; RI 19; RK 19; RK 25; RK 31; UNCLASSIFIED DRUG;

ALPHA HELIX; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BIOFILM; BIOMASS; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG STRUCTURE; EUKARYOTIC CELL; HUMAN; HUMAN CELL; INFRARED OCULOGRAPHY; INFRARED RADIATION; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SESSILE SPECIES;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BIOFILMS; CATHELICIDINS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; L-LACTATE DEHYDROGENASE; MICROBIAL VIABILITY; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PROPIDIUM; PSEUDOMONAS AERUGINOSA; SPECIES SPECIFICITY; SPECTROPHOTOMETRY, INFRARED;

EID: 84868028186     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00918-12     Document Type: Article

References (45)

1. Bals R, Wang X, Zasloff M, Wilson JM. 1998. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. U. S. A. 95:9541-9546.
2. Bolscher JG, et al. 2011. Sortase A as a tool for high-yield histatin cyclization. FASEB J. 25:2650-2658.
3. Braff MH, et al. 2005. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 174:4271-4278.
4. Cerf E, et al. 2009. Antiparallel β-sheet: a signature structure of the oligomeric amyloid β-peptide. Biochem. J. 421:415-423.
5. Chirgadze YN, Nevskaya NA. 1976. Infrared spectra and resonance interaction of amide-I vibration of the antiparallel-chain pleated sheet. Biopolymers 15:607-625.
6. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
7. Dean SN, Bishop BM, van Hoek ML. 2011. Susceptibility of Pseudomonas aeruginosa biofilm to alpha-helical peptides: D-enantiomer of LL-37. Front. Microbiol. 2:128.
8. de Jongh HHJ, Goormaghtigh E, Ruysschaert JM. 1997. Amide-proton exchange of water-soluble proteins of different structural classes studied at the submolecular level by infrared spectroscopy. Biochemistry 36:13603-13610.
9. de la Fuente-Núñez C, et al. 2012. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimi-crob. Agents Chemother. 56:2696-2704.
10. den Hertog AL, et al. 2006. The human cathelicidin peptide LL-37 and truncated variants induce segregation of lipids and proteins in the plasma membrane of Candida albicans. Biol. Chem. 387:1495-1502.
11. Drenkard E, Ausubel FM. 2002. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740-743.
12. Emerson J, Rosenfield M, McNamara S, Ramsey B, Gibson RL. 2002. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 34:91-100.
13. Goeres DM, et al. 2005. Statistical assessment of a laboratory method for growing biofilms. Microbiology 151:757-762.
14. Goormaghtigh E, Ruysschaert JM, Raussens V. 2006. Evaluation of the information content in infrared spectra for protein secondary structure determination. Biophys. J. 90:2946-2957.
15. Gordon YJ. 2005. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr. Eye Res. 30:385-394.
16. Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557.
17. Høiby N, Koch C. 1990. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 45:881-884.
18. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Ager-berth B. 1998. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 273:3718-3724.
19. Kanthawong S, et al. 2010. Antimicrobial activities of LL-37 and its truncated variants against Burkholderia thailandensis. Int. J. Animicrob. Agents 36:447-452.
20. Kanthawong S, et al. 2012. Antimicrobial and antibiofilm activity of LL-37 and its truncated variants against Burkholderia pseudomallei. J. An-timicrob. Agents 39:39-44.
21. Kapoor R, et al. 2011. Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 55:3054-3057.
22. Lacroix E, Viguera AR, Serrano L. 1998. Elucidating the folding problem of a-helices: local motifs, long-range electrostatics, ionic-strength dependence and prediction of NMR parameters. J. Mol. Biol. 284:173-191.
23. Moncla BJ, Pryke K, Rohan LC, Graebing PW. 2011. Degradation of naturally occurring and engineered antimicrobial peptides by proteases. Adv. Biosci. Biotechnol. 2:404-408.
24. Nagant C, et al. 2010. Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms. Appl. Microbiol. Biotechnol. 88:251-263.
25. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aero-bically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
26. Nguyen LT, Haney EF, Vogel HJ. 2011. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 29:464-472.
27. Oberg KA, Ruysschaert JM, Goormaghtigh E. 2003. Rationally selected basis proteins: a new approach to selecting proteins for spectroscopic secondary structure analysis. Protein Sci. 12:2015-2031.
28. O'Toole G, Kaplan HB, Kolter R. 2000. Biofilm formation as microbial development. Annu. Rev. Microbiol. 54:49-79.
29. Overhage J, et al. 2008. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76:4176-4182.
30. Porcelli F, et al. 2008. NMR structure of the cathelicidin-derived human antimicrobial peptide LL-37 in dodecylphosphocholine micelles. Biochemistry 47:5565-5572.
31. Sandgren S, et al. 2004. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J. Biol. Chem. 279:17951-17956.
32. Seil M, El Ouaaliti M, Dehaye JP. 2012. Secretion of IL-1β triggered by dynasore in murine peritoneal macrophages. Innate Immun. 18:241-249.
33. Seil M, et al. 2010. Regulation by CRAMP of the responses of murine peritoneal macrophages to extracellular ATP. Biochim. Biophys. Acta 1798:569-578.
34. Sigurdardottir T, et al. 2006. In silico identification and biological evaluation of antimicrobial peptides based on human cathelicidin LL-37. Antimicrob. Agents Chemother. 50:2983-2989.
35. Singh PK, et al. 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762-764.
36. Sørensen OE, et al. 2001. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97:3951-3959.
37. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. 2000. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J. Microbiol. Methods 40:175-179.
38. Takahashi D, Shukla SK, Prakash O, Zhang G. 2010. Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity. Biochimie 92:1236-1241.
39. Tomasinsig L, et al. 2009. Structure dependence of biological activities for primate cathelicidins. J. Pept. Sci. 15:576-582.
40. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 42:2206-2214.
41. Vigano C, Manciu L, Buyse F, Goormaghtigh E, Ruysschaert JM. 2000. Attenuated total reflection IR spectroscopy as a tool to investigate the structure, orientation and tertiary structure changes in peptides and membrane proteins. Biopolymers 55:373-380.
42. Wang G. 2008. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J. Biol. Chem. 283:32637-32643.
43. Wong JH, et al. 2011. Antifungal action of human cathelicin fragment (LL13-37) on Candida albicans. Peptides 32:1996-2002.
44. Zanetti M, Gennaro R, Skerlavaj B, Tomasinsig L, Circo R. 2002. Cathelicidin peptides as candidates for a novel class of antimicrobials. Curr. Pharm. 8:779-793.
45. Zhang L, et al. 2005. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother. 49:2921-2927.